Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12031279 | 0.82 | LMNA (0.39) | SPHK2SPHK1CYP3A4HSD17B10 | |
| SCHEMBL3962044 | 0.79 | SPHK1 (0.38) | SPHK2SPHK1CYP3A4HSD17B10 | |
| SCHEMBL11858528 | 0.79 | SPHK1 (0.42) | SPHK2SPHK1CYP3A4HSD17B10 | |
| SCHEMBL25726088 | 0.78 | LMNA (0.36) | SPHK2SPHK1CYP3A4HSD17B10 | |
| SCHEMBL12437244 | 0.78 | ALDH1A1 (0.36) | — | |
| SCHEMBL26719977 | 0.78 | SPHK1 (0.37) | SPHK2SPHK1CYP3A4HSD17B10 | |
| SCHEMBL16248567 | 0.78 | LMNA (0.36) | SPHK2SPHK1CYP3A4HSD17B10 | |
| SCHEMBL25726084 | 0.78 | LMNA (0.36) | SPHK2SPHK1CYP3A4HSD17B10 | |
| SCHEMBL19245588 | 0.77 | — | — | |
| SCHEMBL31086433 | 0.76 | SPHK1 (0.44) | SPHK2SPHK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-8933110-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140308243-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-8785487-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140308243-A1 | HEPATITIS C VIRUS INHIBITORS | ZC3HAV1, ZC3HAV1L, HAVCR2 | SPHK2 3124/4885SPHK1 2944/4885CYP3A4 428/4885 |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | SPHK2 3335/4885SPHK1 3134/4885CYP3A4 737/4885 |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | NSUN2, HCCS, HAVCR2 | SPHK2 3158/4885SPHK1 2989/4885CYP3A4 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.